120 related articles for article (PubMed ID: 37803521)
21. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
[TBL] [Abstract][Full Text] [Related]
22. [Correlation between metabolic syndrome and prognosis of patients with clear cell renal cell carcinoma].
Zuo MN; DU YQ; Yu LP; Dai X; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):636-643. PubMed ID: 35950385
[TBL] [Abstract][Full Text] [Related]
23. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
25. Differences in Overall and Cancer-specific Survival of Patients Presenting With Chromophobe Versus Clear Cell Renal Cell Carcinoma: A Propensity Score Matched Analysis.
Frees S; Kamal MM; Knoechlein L; Bell R; Ziesel C; Neisius A; Thomas C; Brenner W; Jäger W; Thüroff JW; Roos FC
Urology; 2016 Dec; 98():81-87. PubMed ID: 27262395
[TBL] [Abstract][Full Text] [Related]
26. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
27. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus.
Tilki D; Nguyen HG; Dall'Era MA; Bertini R; Carballido JA; Chromecki T; Ciancio G; Daneshmand S; Gontero P; Gonzalez J; Haferkamp A; Hohenfellner M; Huang WC; Koppie TM; Lorentz CA; Mandel P; Martinez-Salamanca JI; Master VA; Matloob R; McKiernan JM; Mlynarczyk CM; Montorsi F; Novara G; Pahernik S; Palou J; Pruthi RS; Ramaswamy K; Rodriguez Faba O; Russo P; Shariat SF; Spahn M; Terrone C; Vergho D; Wallen EM; Xylinas E; Zigeuner R; Libertino JA; Evans CP
Eur Urol; 2014 Sep; 66(3):577-83. PubMed ID: 23871402
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
[TBL] [Abstract][Full Text] [Related]
29. Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma.
Hutterer GC; Stoeckigt C; Stojakovic T; Jesche J; Eberhard K; Pummer K; Zigeuner R; Pichler M
Urol Oncol; 2014 Oct; 32(7):1041-8. PubMed ID: 25027686
[TBL] [Abstract][Full Text] [Related]
30. Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients.
Piccinelli ML; Barletta F; Tappero S; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Luzzago S; Mistretta FA; Ferro M; Saad F; Shariat SF; Ahyai S; Longo N; Tilki D; Chun FKH; Terrone C; Briganti A; de Cobelli O; Musi G; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):799-806. PubMed ID: 37024421
[TBL] [Abstract][Full Text] [Related]
31. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
32. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
Zhao H; Leppert JT; Peehl DM
PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
[TBL] [Abstract][Full Text] [Related]
33. Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry.
Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
Cancer Res Treat; 2019 Apr; 51(2):758-768. PubMed ID: 30189720
[TBL] [Abstract][Full Text] [Related]
34. The Cleveland Clinic experience with papillary (chromophil) renal cell carcinoma: clinical outcome with histopathological correlation.
Chow GK; Myles J; Novick AC
Can J Urol; 2001 Apr; 8(2):1223-8. PubMed ID: 11375785
[TBL] [Abstract][Full Text] [Related]
35. Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma.
Rosiello G; Larcher A; Fallara G; Giancristofaro C; Martini A; Re C; Cei F; Musso G; Tian Z; Karakiewicz PI; Mottrie A; Bertini R; Salonia A; Necchi A; Raggi D; Briganti A; Montorsi F; Capitanio U
Urol Oncol; 2022 Jun; 40(6):271.e19-271.e27. PubMed ID: 35140049
[TBL] [Abstract][Full Text] [Related]
36. Development and Validation of a Nomogram to Predict Cancer-Specific Survival in Elderly Patients With Papillary Renal Cell Carcinoma.
Zhanghuang C; Wang J; Yao Z; Li L; Xie Y; Tang H; Zhang K; Wu C; Yang Z; Yan B
Front Public Health; 2022; 10():874427. PubMed ID: 35444972
[TBL] [Abstract][Full Text] [Related]
37. Prognostic role of the endothelial cell-specific molecule-1 histopathologic expression in renal cell cancer.
Bocu K; Batur AF; Celik ZE; Gül M; Altıntas E; Kaynar M; Kılıç O; Akand M; Tataroglu SN; Goktas S
Urol Oncol; 2023 Jun; 41(6):297.e1-297.e9. PubMed ID: 37127479
[TBL] [Abstract][Full Text] [Related]
38. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology.
Pichler M; Hutterer GC; Chromecki TF; Jesche J; Kampel-Kettner K; Rehak P; Pummer K; Zigeuner R
J Urol; 2011 Nov; 186(5):1773-7. PubMed ID: 21944989
[TBL] [Abstract][Full Text] [Related]
39. Oncological outcomes of papillary
Cetin T; Celik S; Sozen S; Akdogan B; Izol V; Aslan G; Suer E; Bayazit Y; Karakoyunlu N; Ozen H; Baltaci S; Gokalp F; Tinay I
Arch Ital Urol Androl; 2023 May; 95(2):11218. PubMed ID: 37254924
[TBL] [Abstract][Full Text] [Related]
40. [Diagnostic value of mult-detector CT for papillary renal cell carcinoma and chromophobe renal cell carcinoma].
Liu X; Zou X; Chen H; Fang X; Hu X; Sun R
Zhonghua Zhong Liu Za Zhi; 2015 Jan; 37(1):52-6. PubMed ID: 25877320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
